AstraZeneca buying drug developer Alexion for $39 billion

Pharmaceutical company AstraZeneca says it's buying U.S. drug developer Alexion in a deal worth $39 billion

Via AP news wire
Saturday 12 December 2020 14:42
AstraZenenca Alexion
AstraZenenca Alexion
Leer en Español

Pharmaceutical company AstraZeneca says it is buying U.S. drug developer Alexion in a deal worth $39 billion.

Cambridge, England-based AstraZeneca PLC, which is involved in one of the efforts to develop a COVID-19 vaccine, said Saturday it's using a combination of cash and shares for the acquisition of Boston-based Alexion Pharmaceuticals Inc.

The boards of both companies unanimously approved the transaction, which still needs regulatory and shareholder approval. The deal is expected to close in the third quarter of 2021.

"This acquisition allows us to enhance our presence in immunology," AstraZeneca CEO Pascal Soriot said in a statement.

AstraZeneca and Oxford University have jointly developed a coronavirus vaccine that British and Canadian regulators are assessing, alongside a rival effort by U.S. drugmaker Pfizer and Germany’s BioNTech that has already earned some emergency approvals, and another by U.S. biotechnology company Moderna.